Tutti gli studi
Attivo ma non reclutanteFASE2INTERVENTISTICO

Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)

The AGLOW study is a research project focusing on a new medicine, VX-407, for adults with Autosomal Dominant Polycystic Kidney Disease (ADPKD). This condition causes fluid-filled sacs (cysts) to grow in the kidneys, which can lead to kidney damage over time. The main goal of this study is to find out if VX-407 can slow down the growth of these cysts by measuring changes in kidney size. Researchers will also be checking if the medicine is safe to use, if people can tolerate it well, and how the body processes it. This early-stage study is an important step in understanding if VX-407 could be a future treatment option for ADPKD, specifically for patients with certain genetic features.

A colpo d'occhio

Stato
Attivo ma non reclutante
Fase
FASE2
Sponsor
Vertex Pharmaceuticals Incorporated
Obiettivo di iscrizione
26
Inizio
19 Nov 2025
Completamento stimato
31 Dic 2027

Di cosa tratta questo studio?

This study, named AGLOW, is investigating a new medication called VX-407 for people living with Autosomal Dominant Polycystic Kidney Disease (ADPKD). ADPKD is a genetic condition where fluid-filled sacs, known as cysts, develop and multiply in the kidneys. Over time, these cysts can enlarge the kidneys and reduce their ability to function properly, potentially leading to kidney failure.

The main aim of this research is to see how VX-407 affects the size of the kidneys, as increased kidney size is often a sign of ADPKD progressing. Researchers will be measuring your kidney volume (adjusted for your height) to see if the medicine can slow down cyst growth. They also want to understand if VX-407 is safe for patients to use, if it causes any side effects, and how the body absorbs, distributes, and removes the medicine (what scientists call 'pharmacokinetics').

This is an early-stage study (Phase 2a), which means it's one of the first times this specific medicine is being tested in a larger group of patients to assess its effectiveness and safety. The insights gained from AGLOW will be crucial in deciding if VX-407 has the potential to become a treatment for ADPKD, particularly for individuals who have specific genetic changes in their PKD1 gene.

Punti chiave

  • This study is testing a new medicine (VX-407) for ADPKD.
  • It aims to see if the medicine can slow down kidney cyst growth.
  • Participation requires regular hospital visits and health monitoring.
  • You must be 18-65 years old and have a specific type of ADPKD.
  • Potential benefits and risks will be fully explained before you decide to join.
  • Puoi ritirarti dallo studio in qualsiasi momento.

Chi può essere idoneo?

To join this study, you must have been diagnosed with Autosomal Dominant Polycystic Kidney Disease (ADPKD) and be willing to attend all scheduled appointments and follow the study instructions. Your kidney cysts would also need to meet certain measurements seen on a special MRI scan (Mayo imaging classification 1B with a kidney size of at least 250 mL/m, 1C, 1D, or 1E).

Your kidneys also need to be working at a certain level. Specifically, your estimated kidney function (eGFR) must be 25 millilitres per minute per 1.73 square metre or higher. You must be between 18 and 65 years old, and the study is open to both men and women.

There are also some reasons why you wouldn't be able to join. For example, if you have another kidney condition not related to ADPKD, or if you've had a kidney or other organ transplant, or if you've had a kidney removed. People who are currently on dialysis or expect to start dialysis within the next year would also not be able to participate. The study team will review all your medical information to make sure it's safe and appropriate for you to join.

Questo studio potrebbe fare al caso tuo?

Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.

  1. Do you have a diagnosis of ADPKD?
  2. Hai tra i 18 e i 65 anni?
  3. Are you able to attend clinic visits regularly?
  4. Has an MRI scan shown your kidney condition meets certain criteria (like Mayo 1B with a specific size, 1C, 1D, or 1E)?
  5. Is your kidney function (eGFR) at least 25 mL/min/1.73 m² or higher?
  6. Have you not had a kidney transplant or other major organ transplant?
Rispondi a ogni domanda per vedere il tuo risultato.

Cosa comporta la partecipazione?

If you decide to take part in the AGLOW study, you will have regular visits to the clinic so the research team can monitor your health and the effects of the study medicine. These visits will involve various tests and assessments, including blood and urine samples, and possibly repeat MRI scans to measure your kidney size. You will be taking the study medicine, VX-407, as directed by the study team. You will also have follow-up appointments after you stop taking the medicine to ensure your health is still being monitored. The total duration of your involvement in the study will be explained in detail by the research team.

Rischi e benefici potenziali

Taking part in any clinical study carries potential benefits and risks. For this study, a potential benefit could be that VX-407 might help slow down the progression of your ADPKD, although this is not guaranteed as it's a new medicine being tested. It's also possible you may not experience any direct benefits. Potential risks could include side effects from the medication or discomfort from study procedures like blood tests or MRI scans. The research team will explain all known or expected risks in detail. Remember, participation is completely voluntary, and you have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (43)

  • Alabama Kidney Research
    Codice postale verificato
    Alabaster, United States
  • UAB Nephrology Research at CH19
    Codice postale verificato
    Birmingham, Stati Uniti
  • Kaiser Permanente Los Angeles Medical Center
    Codice postale verificato
    Los Angeles, Stati Uniti
  • UCSF Clinical Research Center at Parnassus
    Codice postale verificato
    San Francisco, Stati Uniti
  • Nephrology & Hypertension Associates, PC
    Codice postale verificato
    Middlebury, United States
  • Yale University - Yale Nephrology Clinical Research Clinic
    Codice postale verificato
    New Haven, Stati Uniti
  • Mayo Clinic - Jacksonville
    Codice postale verificato
    Jacksonville, Stati Uniti
  • Emory School of Medicine - Renal Division
    Codice postale verificato
    Atlanta, Stati Uniti
  • Renal Associates
    Codice postale verificato
    Columbus, Stati Uniti
  • UChicago Medicine - Duchossois Center for Advanced Medicine - Nephrology
    Codice postale verificato
    Chicago, Stati Uniti
  • University of Iowa Health Care Medical Center- Nephrology
    Codice postale verificato
    Iowa City, Stati Uniti
  • Clinical & Translational Science Unit (CTSU) - Nephrology
    Codice postale verificato
    Kansas City, Stati Uniti

Domande comuni

What is ADPKD?

ADPKD stands for Autosomal Dominant Polycystic Kidney Disease. It's a genetic condition where fluid-filled sacs called cysts grow in your kidneys, which can affect their function over time.

What is VX-407?

VX-407 is a new medicine being studied. This research project is trying to find out if it's safe and effective for treating ADPKD.

Riceverò sicuramente il nuovo medicinale?

In some studies, participants are randomly assigned to receive the study medicine or a placebo (a dummy medicine). The researchers will explain exactly what this means for you.

Will I have to pay to join this study?

No, you will not have to pay to participate in the study, and study-related medical care and the study medicine will be provided free of charge. Travel expenses may also be reimbursed.

E se cambio idea sulla partecipazione?

You have the right to leave the study at any time, for any reason, without having to explain why. Your decision will not affect your ongoing medical care.

Come saperne di più

Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.

Discussione

Discussione della comunità

Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.